Biotech

All Articles

Lilly articles even more favorable data on its own once a week insulin possibility

.On the heels of an FDA rejection for its own primary rivalrous Novo Nordisk, Eli Lilly is making he...

IN 8bio halts phase 2 trial, gives up one-half of labor force

.Just a few months after dosing the 1st individual in a period 2 test for freshly diagnosed glioblas...

Lilly, Haya ink $1B biobuck excessive weight contract to browse black genome

.Eli Lilly's search for obesity aim ats has led it to the black genome. The Big Pharma has created a...

ArsenalBio raises $325M, turns off of past lead property

.Toolbox Biosciences is going on up. The tissue therapy provider has added $325 thousand in ammo wit...

Lilly- supported weight-loss biotech documents IPO

.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted t...

Aelis' cannabis usage medication flunks phase 2b, steering Indivior to reassess $100M alternative

.Aelis Farma's hopes of protecting a fast, good choice on a $one hundred thousand possibility settle...

ProKidney standstills phase 3 test not needed to have for cell therapy authorization

.ProKidney has stopped some of a pair of period 3 tests for its own tissue treatment for renal ailme...

Vaxcyte rises on 'impressive' 31-valent PCV gain against Pfizer

.Vaxcyte unveiled what analysts referred to as "magnificent" period 1/2 records for its own 31-valen...

Recursion's human brain illness trial presents scant documentation of efficacy

.Recursion has actually discovered via a very early test of its tech-enabled strategy to medication ...

Acepodia, Pfizer click with each other for chemistry-based tissue treatment

.Call it an instance of excellent chemical make up: Acepodia, a biotech based on Nobel Prize-winning...